TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05503147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
Study: NCT04933942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Oral administration of Lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Oral administration of Lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Subcutaneous administration of Romiplostim
Study: NCT06437899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical botulinum toxin A injection unter local anaesthesia
Description: Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical botulinum toxin A injection unter local anaesthesia
Description: Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor.
Study: NCT05854589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride Granules
Description: Sodium Chloride crystals
Study: NCT04924296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 s.c. + Steroids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. + Steroids
Study: NCT06061900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group exercise program
Description: Group fitness program
Study: NCT05030064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal flora capsule
Description: This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
Study: NCT05639322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine + Cognitive Behavioral Therapy
Description: Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
Study: NCT05093920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin-Eluting Beads
Description: * The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin-Eluting Beads
Description: * The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.
Study: NCT05324423

Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine
Description: Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
Study: NCT05942118

Intervention type: PROCEDURE
Intervention: Breast conservative surgery
Description: Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization

Intervention type: PROCEDURE
Intervention: Breast conservative surgery
Description: Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
Study: NCT04871802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taxifolin Aqua
Description: Dietary supplement
Study: NCT06398964

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3-hydroxybutyrat
Description: The intervention is administered as a drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo drink
Description: The intervention is administered as a drink.
Study: NCT05088993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training
Description: This group received antigravity treadmill training 100% weight bearing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise program
Description: This group received the conventional exercise program only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise program
Description: This group received the conventional exercise program only.
Study: NCT05209308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Zandelisib taken orally for 7 days of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Zandelisib taken orally for 7 days of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally - Ramp up weeks 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally - Ramp up weeks 1-5
Study: NCT05854589

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Plain distilled water
Study: NCT05313074

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac vaccine
Description: An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CoronaVac vaccine
Description: An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
Study: NCT05353231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Feedback Awareness and Control Training (A-FACT)
Description: A-FACT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control.~Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Following a fixation que, the auditory neutral or negative simulated thought stimulus is delivered, and 500ms prior to termination of the auditory stimulus, a visual stimulus is presented until participants categorize the visual stimulus as greater than or smaller than 5 objects. Latency to disengage attention from each thought stimuli, at the trial-level, is repeatedly measured, and after each negative thought stimulus, trial-level feedback on the latency to disengage is delivered back to participants through a visual scale representing their attentional bias. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Disengagement from Thoughts Training (MDTT)
Description: MDTT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Participants will first learn and practice a focused attention on the breath meditation. Then, participants will practice pressing a button each time they notice an inhalation or exhalation during the focused attention meditation. Next, during the meditation, participants will be presented the auditory neutral or negative simulated thought stimuli and will train internal attentional control by repeatedly disengaging their attention from these stimuli and back to their breath MDTT will thus entail 80 trials (40 negative, 40 neutral, ITI ≈ 10sec) during the focused attention on the breath meditation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: The condition is designed as a placebo control for the Attention Feedback Awareness and Control Training (A-FACT) training condition. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Rather than the quantity categorization task with trial-level feedback, participants only engage in the quantity categorization task. The task is identical in all other ways to the A-FACT condition. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.
Study: NCT04728581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
Study: NCT05221112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagonal pattern training
Description: patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single plane training
Description: patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
Study: NCT05492760

Intervention type: DEVICE
Intervention: cryoballoon ablation
Description: Patients with AF will accept cryoballoon ablation.
Study: NCT05801055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone
Description: The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
Study: NCT05045677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital DBT skills intervention
Description: The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
Study: NCT04265859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Training
Description: The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
Study: NCT04731207

Intervention type: DEVICE
Group type: OTHER
Intervention: Optovue®
Description: Optical coherence tomography and optical coherece tomography angiography
Study: NCT04265859

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Training
Description: The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
Study: NCT05794711

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
Study: NCT06386341

Intervention type: PROCEDURE
Intervention: Maxillomandibular Advancement Surgery
Description: Surgery where the upper and lower jaw are repositioned.

Intervention type: PROCEDURE
Intervention: Maxillomandibular Advancement Surgery
Description: Surgery where the upper and lower jaw are repositioned.
Study: NCT04265859

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
Study: NCT04728581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a gelatinous capsule without an active ingredient
Study: NCT04905173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squat-to-stand maneuver
Description: Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amyl nitrite inhalation
Description: Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valsalva
Description: Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
Study: NCT06220422

Intervention type: PROCEDURE
Intervention: Standard Department procedure for managing direct-acting oral anticoagulants
Description: Standard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021

Intervention type: PROCEDURE
Intervention: New Department procedure for managing direct-acting oral anticoagulants
Description: New Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021
Study: NCT05673044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified Studer ileal neobladder
Description: orthotopic ileal neobladders

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified Studer ileal neobladder
Description: orthotopic ileal neobladders
Study: NCT05294172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 4-6 cycles for combined therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 4-6 cycles for combined therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 4-6 cycles for combined therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 4-6 cycles for combined therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4-6 cycles for combined therapy.Placebo maintenance.
Study: NCT06332326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive vagus nerve stimulation
Description: non-invasive vagus nerve stimulation: patients will receive non-invasive vagus nerve stimulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vestibular rehabilitation
Description: vestibular rehabilitation: Patients will be given specially structured vestibular rehabilitation exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vestibular rehabilitation
Description: vestibular rehabilitation: Patients will be given specially structured vestibular rehabilitation exercises.
Study: NCT06305195

Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate variability test
Description: First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate variability test
Description: First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate variability test
Description: First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed.
Study: NCT04695925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 MG [Tagrisso]
Description: osimertinib 80 mg po qd until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib 80 MG [Tagrisso]
Description: osimertinib 80 mg po qd until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 MG Injection
Description: pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin area under curve 5 intravenously every 3 weeks for four cycles
Study: NCT06456060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvogyl
Description: Alvogyl soaked in a sterile gauze will be applied to cover the socket.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honey
Description: Honey soaked in a sterile gauze will be applied to cover the socket.
Study: NCT05819554

Intervention type: PROCEDURE
Intervention: Trans-sphenoidal surgery
Description: Surgical removal of pituitary tumor by trans-sphenoidal approach

Intervention type: PROCEDURE
Intervention: Trans-sphenoidal surgery
Description: Surgical removal of pituitary tumor by trans-sphenoidal approach

Intervention type: PROCEDURE
Intervention: Trans-sphenoidal surgery
Description: Surgical removal of pituitary tumor by trans-sphenoidal approach

Intervention type: PROCEDURE
Intervention: Trans-sphenoidal surgery
Description: Surgical removal of pituitary tumor by trans-sphenoidal approach
Study: NCT05878587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen
Description: Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thermotherapy+ TENS+ low intensity high repetition exercises
Description: The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.